Scholarlink

Background <p>The optimal hemoglobin (Hb) threshold to trigger red blood cell transfusions (RBCT) in subarachnoid hemorrhage (SAH) patients is unclear. This study evaluated the impact of liberal versus restrictive transfusion strategies on neurological outcome in patients with SAH.</p> Methods <p>This is a pre-planned secondary analysis of the “TRansfusion Strategies in Acute brain INjured Patients” (TRAIN) study. We included all SAH patients from the original study that were randomized to receive RBCT when Hb levels dropped below 9&#xa0;g/dL (liberal group) or 7&#xa0;g/dL (restrictive group). The primary outcome was an unfavorable neurological outcome at 180&#xa0;days, defined by a Glasgow Outcome Scale Extended score of 1–5.</p> Results <p>Of the 190 SAH patients in the trial, 188 (98.9%) had data available for the primary outcome, with 86 (45.3%) in the liberal group and 102 (53.6%) in the restrictive group. Patients in the liberal group were older than in the restrictive group, but otherwise had similar baseline characteristics. Patients in the liberal group received more RBCT and showed higher Hb levels over time. At 180&#xa0;days, 57 (66.3%) patients in the liberal group and 78 (76.4%) in the restrictive group had unfavorable outcomes (risk ratio, RR 0.87; 95% confidence intervals, 95% CI 0.71–1.04). Patients in the liberal group had a significantly lower risk of cerebral ischemia (RR 0.63; 95% CI 0.41–0.97). In a multivariate analysis, randomization to the liberal group was associated with a lower risk of unfavorable outcome (RR 0.83, 95% CI 0.70–0.99).</p> Conclusions <p>A liberal transfusion strategy was not associated with a lower incidence of unfavorable outcome after SAH when compared to a restrictive strategy. However, in a multivariable analysis adjusted for confounders randomization to the liberal group was associated with lower risk of unfavorable outcome. The occurrence of cerebral ischemia was significantly lower in the liberal transfusion strategy group.</p> <i>Trial registration</i> <p>ClinicalTrials.gov number—NCT02968654 registered on November 16th, 2016.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Liberal versus restrictive transfusion strategies in subarachnoid hemorrhage: a secondary analysis of the TRAIN study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月7日

查看全文
  • Chahnez Taleb,
  • Elisa Gouvea Bogossian,
  • Carla Bittencour Rynkowski,
  • Kirsten Møller,
  • Piet Lormans,
  • Manuel Quintana Diaz,
  • Anselmo Caricato,
  • Luigi Zattera,
  • Pedro Kurtz,
  • Geert Meyfroidt,
  • Herve Quintard,
  • Maria Celeste Dias,
  • Angelo Giacomucci,
  • Charlotte Castelain,
  • Russell Chabanne,
  • Pilar Marcos-Neira,
  • Stepani Bendel,
  • Ahmed Subhy Alsheikhly,
  • Mohamed Elbahnasawy,
  • Samuel Gay,
  • Maximilian D’Onofrio,
  • Konstantin A. Popugaev,
  • Nikolaos Markou,
  • Pierre Bouzat,
  • Jean-Louis Vincent,
  • Fabio Silvio Taccone,
  • Marco Antonio Cardoso Ferreira,
  • Rafael Badenes,
  • Christian Baastrup Sondergaard,
  • Kirsten Colpaert,
  • Leticia Petterson,
  • Claudia Díaz,
  • Andrés Saravia,
  • Ahmad Bayrlee,
  • Laura Nedolast,
  • Hussam Elkambergy,
  • Haamid Siddique,
  • Jihad Mallat,
  • Nahla AlJaberi,
  • Samer Shoshan,
  • Ayo Mandi,
  • Bruno De Oliveira,
  • Malligere Prasanna,
  • Rehan Haque,
  • Dnyaneshwar Munde,
  • Sara Chaffee,
  • Fatma Alawadhi,
  • Jamil Dibu,
  • Eija Junttila,
  • Teemu Luoto,
  • Simona Šteblaj,
  • Jacques Creteur,
  • Dominique Durand,
  • Caroline Abbenhuijs,
  • Nancy Itesa Matumikina,
  • Filippo Annoni,
  • Leda Nobile,
  • Miguel Ulloa Bersatti,
  • Igor Yovenko,
  • Alexander Tsarev,
  • Jasperina Dubois,
  • Evy Voets,
  • Luc Janssen,
  • Luigi Zattera,
  • Leire Pedrosa,
  • Berta Monleon Lopez,
  • Ainhoa Serrano,
  • Nekane Romero-García,
  • Xavier Wittebole,
  • Antonio Maria Dell’Anna,
  • Camilla Gelormini,
  • Eleonora Stival,
  • Pilar Marcos Neira,
  • Regina Roig Pineda,
  • Lara Bielsa Berrocal,
  • Maite Misis del Campo,
  • Jorge H. Mejía-Mantilla,
  • Ángela Marulanda,
  • Wojciech Dabrowski,
  • Rune Damgaard Nielsen,
  • Markus Harboe Olsen,
  • Helene Ravnholt Jensen,
  • Ida Møller Larsen,
  • Roberta Tallarico,
  • Umberto Lucangelo,
  • Maria Isabel Gonzalez Perez,
  • Carole Ichai,
  • Karim Asenhoune,
  • Karim Lakhal,
  • Charlotte Fernandez-Canal,
  • Samuel Gay,
  • Marie Lebouc,
  • David Bougon,
  • Etienne Escudier,
  • Michel Sirodot,
  • Albrice Levrat,
  • Alix Courouau,
  • Jacques Duranteau,
  • Aurore Rodrigues,
  • Naima Makouche,
  • Gilles Francony,
  • Olivier Vincent,
  • Perrine Boucheix,
  • Clotilde Schilte,
  • Marie Cecile Fevre,
  • Thomas Mistral,
  • Marion Richard,
  • Samia Salah,
  • Pierluigi Banco,
  • Angelina Pollet,
  • Anais Adolle,
  • Thomas Gargadennec,
  • Patricia Dias,
  • Gwenaelle Desanglois,
  • Alexia Meheut,
  • Pauline Cam,
  • Liese Mebis,
  • Alexandra Hendrickx,
  • Pieter Wouters,
  • Sylvia Van Hulle,
  • Alain D’Hondt,
  • Marjorie Beumier,
  • Marc Burgeois,
  • Olivier Simonet,
  • Frederic Vallot,
  • Pablo Centeno,
  • Matias Anchorena,
  • Ximena Benavente,
  • Nydia Funes,
  • Antonio Barra de Oca,
  • Gabriela Izzo,
  • Charlotte Castelain,
  • Filip Soetens,
  • Mario Arias,
  • Diego Morocho,
  • Manuel Jabaja,
  • Diego Tutillo,
  • Elena Perez Solada,
  • Pilar Justo,
  • Amparo Lopez Gomez,
  • Sara Alcantara,
  • Francisco Chico,
  • Maria Fernanda Garcia,
  • Fabricio Picoita,
  • Stela Velasco Eichler,
  • Gabriela Nonticuri Bianchi,
  • João Pedro Britz,
  • Jaqueline Almeida Pimentel,
  • Mário Sérgio Fernandes,
  • Hedi Gharsallah,
  • Zied Hajjej,
  • Walid Samoud,
  • Oleg Grebenchikov,
  • Valery Likhvantsev,
  • Elena Stroiteleva,
  • Nikolaos Markou,
  • Dimitra Bakali,
  • Dionysia Koutrafouri,
  • Sara Maccherani,
  • Janneke Horn,
  • Arezoo Ahmadi,
  • Lien Decaesteker,
  • Daphne Decruyenaere,
  • Ruth Demeersseman,
  • Yves Devriendt,
  • Karen Embo,
  • Ditty van Duijn,
  • Patricia Ormskerk,
  • Melanie Glasbergen-van Beijeren,
  • Raphael Cinotti,
  • Cassia Righy,
  • Serena Silva,
  • Catherine Vandewaeter,
  • Daniel Lemke,
  • Ata Mahmoodpoor,
  • Aaron Blandino-Ortiz,
  • Mathieu Van der Jagt,
  • Walter Videtta

摘要

Background

The optimal hemoglobin (Hb) threshold to trigger red blood cell transfusions (RBCT) in subarachnoid hemorrhage (SAH) patients is unclear. This study evaluated the impact of liberal versus restrictive transfusion strategies on neurological outcome in patients with SAH.

Methods

This is a pre-planned secondary analysis of the “TRansfusion Strategies in Acute brain INjured Patients” (TRAIN) study. We included all SAH patients from the original study that were randomized to receive RBCT when Hb levels dropped below 9 g/dL (liberal group) or 7 g/dL (restrictive group). The primary outcome was an unfavorable neurological outcome at 180 days, defined by a Glasgow Outcome Scale Extended score of 1–5.

Results

Of the 190 SAH patients in the trial, 188 (98.9%) had data available for the primary outcome, with 86 (45.3%) in the liberal group and 102 (53.6%) in the restrictive group. Patients in the liberal group were older than in the restrictive group, but otherwise had similar baseline characteristics. Patients in the liberal group received more RBCT and showed higher Hb levels over time. At 180 days, 57 (66.3%) patients in the liberal group and 78 (76.4%) in the restrictive group had unfavorable outcomes (risk ratio, RR 0.87; 95% confidence intervals, 95% CI 0.71–1.04). Patients in the liberal group had a significantly lower risk of cerebral ischemia (RR 0.63; 95% CI 0.41–0.97). In a multivariate analysis, randomization to the liberal group was associated with a lower risk of unfavorable outcome (RR 0.83, 95% CI 0.70–0.99).

Conclusions

A liberal transfusion strategy was not associated with a lower incidence of unfavorable outcome after SAH when compared to a restrictive strategy. However, in a multivariable analysis adjusted for confounders randomization to the liberal group was associated with lower risk of unfavorable outcome. The occurrence of cerebral ischemia was significantly lower in the liberal transfusion strategy group.

Trial registration

ClinicalTrials.gov number—NCT02968654 registered on November 16th, 2016.